Elena M. Elli

Monza, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Association of hypomethylating agents + venetoclax in the real-life treatment of Myeloproliferative Neoplasms in blastic phase.

Journal: Leukemia research

Published: March 06, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer

Published: February 19, 2026

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer

Published: December 16, 2025

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Journal: Annals of hematology

Published: November 14, 2025

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study.

Health-related quality of life and symptom profile of patients with BCR::ABL1-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational study.

Journal: HemaSphere

Published: August 05, 2025

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Neutrophil to lymphocyte ratio at diagnosis predicts venous thrombosis in prefibrotic primary myelofibrosis: results from a multicenter cooperative study.

Journal: Annals of hematology

Published: July 23, 2025

An Uncommon Presentation of Sweet's Syndrome in Primary Myelofibrosis.

An Uncommon Presentation of Sweet's Syndrome in Primary Myelofibrosis.

Journal: Case reports in hematology

Published: June 05, 2025

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.

Journal: Cancer

Published: May 05, 2025

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.

Journal: Annals of hematology

Published: March 25, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026